Phase II study (KAMELEON) of single‐agent T‐DM1 in patients with HER2‐positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma

Autor: Elisabeth G. E. deVries, Josef Rüschoff, Martijn Lolkema, Josep Tabernero, Luca Gianni, Emile Voest, Derk Jan A. deGroot, Daniel Castellano, Gilles Erb, Julia Naab, Margarita Donica, Regula Deurloo, Michiel S. van derHeijden, Giuseppe Viale

Publikováno v: Cancer Medicine, Vol 12, Iss 11, Pp 12071-12083 (2023)

Abstract The antibody‐drug conjugate trastuzumab emtansine (T‐DM1) is approved for human epidermal growth factor receptor 2 (HER2/ERBB2)–positive breast cancer. We aimed to study tumor HER2 expression and its effects on T‐DM1 responses in pat

Externí odkaz: https://doaj.org/article/0f7c9c9a50584cb282318c9ac1965648

An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma

Autor: Piotr Rutkowski, Wilson H. Miller, Ivana Krajsová, Christian U. Blank, Paola Queirolo, Ana Arance, Paul Lorigan, Mario Mandalà, Geke A. P. Hospers, Bart Neyns, Jacob Schachter, Vanna Chiarion Sileni, James Larkin, Martina Makrutzki, Enrique Espinosa, Alexander Guminski, Margarita Donica, Axel Hauschild, Gabriela Liszkay, Marta Nyakas, Michele Del Vecchio, Paolo A. Ascierto, Claus Garbe, Helen Gogas, Michael P. Brown

Publikováno v: European Journal of Cancer, 107, 175-185. ELSEVIER SCI LTD

BACKGROUND: The oncogenic BRAF inhibitor vemurafenib improves outcomes for patients with advanced BRAFV600 mutation-positive melanoma compared with cytotoxic chemotherapy. Vemurafenib is now approved for use in this patient population.PATIENTS AND ME

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4770200b8acfba16c98dc5dbd5caf591
https://doi.org/10.1016/j.ejca.2018.11.018

Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial

Autor: Thomas Hatschek, Peter M. Ellis, Rachel Wuerstlein, Filippo Montemurro, Antonio Antón, Catherine M. Kelly, C. Pena-Murillo, Etienne Brain, Carlos H. Barrios, Margarita Donica, M. Yilmaz, Suzette Delaloge

Publikováno v: Zaguán: Repositorio Digital de la Universidad de Zaragoza
Universidad de Zaragoza
Zaguán. Repositorio Digital de la Universidad de Zaragoza
instname

Background Patients with brain metastases (BM) from human epidermal growth factor receptor 2 (HER2)-positive breast cancer represent a difficult-to-treat population. Trastuzumab emtansine (T-DM1) has shown potential activity in this subset of patient

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e15488c4009f800f99e635d7b004b7a7
http://zaguan.unizar.es/record/95663

Bevacizumab combined with first-line carboplatin and paclitaxel for metastatic/recurrent/persistent cervical cancer: primary results from the global single-arm phase II CECILIA study

Autor: Lydia Dreosti, Angélica Nogueira-Rodrigues, Giovanni Scambia, Nicoletta Colombo, A. Roszak, Antonio González-Martín, B. Ulker, Andrés Redondo, Mary McCormack, Margarita Donica

Publikováno v: Oral Communication 2 – Cervical Cancer.

Introduction/Background In the phase III GOG240 trial, combining bevacizumab with paclitaxel and cisplatin/topotecan for advanced cervical cancer significantly improved overall and progression-free survival. The single-arm phase II CECILIA study (NCT

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6dac2d4b10781d07085b03df9747fc56
https://doi.org/10.1136/ijgc-2019-esgo.25

An open-label, multicentre safety study of vemurafenib in patients with BRAF

Autor: James, Larkin, Michael P, Brown, Ana M, Arance, Axel, Hauschild, Paola, Queirolo, Michele Del, Vecchio, Paolo A, Ascierto, Ivana, Krajsová, Jacob, Schachter, Bart, Neyns, Claus, Garbe, Vanna Chiarion, Sileni, Mario, Mandalà, Helen, Gogas, Enrique, Espinosa, Geke, Hospers, Paul, Lorigan, Marta, Nyakas, Alex, Guminski, Gabriela, Liszkay, Piotr, Rutkowski, Wilson, Miller, Margarita, Donica, Martina, Makrutzki, Christian, Blank

Publikováno v: European journal of cancer (Oxford, England : 1990). 107

The oncogenic BRAF inhibitor vemurafenib improves outcomes for patients with advanced BRAFIn this open-label, multicentre study, patients with previously treated or untreated melanoma and the BRAFBetween March 2011 and January 2013, 3224 patients wer

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::95135ec815cf764fffa0945b82faf326
https://pubmed.ncbi.nlm.nih.gov/30580112